<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722265</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J302</org_study_id>
    <nct_id>NCT02722265</nct_id>
  </id_info>
  <brief_title>Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension</brief_title>
  <official_title>Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration
      of CS-3150 as monotherapy and in combination with calcium channel blocker or
      renin-angiotensin system inhibitor in patients with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">July 8, 2017</completion_date>
  <primary_completion_date type="Actual">July 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in sitting systolic and diastolic blood pressure</measure>
    <time_frame>week 0 (baseline) to end of weeks 12, 28, and 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hr ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>week 0 (baseline) to end of weeks 12, 28, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and severity of adverse events</measure>
    <time_frame>week 0 (baseline) to end of weeks 12, 28, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and severity of laboratory abnormalities</measure>
    <time_frame>week 0 (baseline) to end of weeks 12, 28, and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <description>CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks</description>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Subjects with essential hypertension, who do not receive any antihypertensive drugs or
             receive calcium channel blocker, angiotensin converting enzyme ACE inhibitor, or
             angiotensin-II receptor blockade ARB during run-in period (Sitting systolic blood
             pressure SBP ≥ 140 mmHg and &lt; 180 mmHg, Sitting diastolic blood pressure DBP ≥ 90 mmHg
             and &lt; 110 mmHg, and mean 24hr SBP ≥ 130 and DBP ≥ 80 mmHg)

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetes mellitus with albuminuria

          -  Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive ACE inhibitor, or
             ARB)

          -  Reversed day-night life cycle including overnight workers

          -  estimated glomerular filtration rate eGFR &lt; 60 mL/min/1.73 m^2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Long-term treatment</keyword>
  <keyword>Mineralocorticoid receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

